Growing expansions in the C9ORF72 gene may lead to earlier onset of amyotrophic lateral sclerosis and/or frontotemporal dementia symptoms with each passing generation.
Thousands of hits on the ol’ noggin during a soccer player’s career might lead to concussive symptoms and, eventually, dementia.
The EPOCH trial of verubecestat was halted for lack of efficacy. APECS trial in prodromal AD continues.
In cell cultures, excess cytoplasmic TDP-43 shut down global translation and triggered formation of protein inclusions.
Transgenic mouse models devoid of gut microbes make fewer Aβ plaques.
Using yeast as springboard, researchers deploy a new computational tool to trace the biology driving α-synuclein pathology in people. The hope: to find pathways that will inform future therapies.
Speaking two languages enhances connections within the brain, which may compensate for neurodegeneration.
A simple blood draw may help distinguish garden-variety PD from other, less common parkinsonian disorders early in disease.
Merck announced a premature end to the EPOCH trial of verubecestat in mild to moderate Alzheimer’s disease. A prespecified interim analysis by an external data-monitoring committee reportedly judged the chance of a clinical benefit to be near zero. The trial had been slated to run until July of this year. Merck’s APECS trial in people with prodromal AD will continue; results are expected by 2019. Commentators expressed disappointment but no surprise.
A new study reports that microbial inhabitants in the intestine stoke Aβ pathology in the brain, at least in mice. Transgenic animals born and raised without an intestinal flora deposited far less Aβ than did their brethren replete with bacteria, and this protection was dashed by introducing fecal microbes from other mice. The researchers proposed that meddling with the microbial milieu could potentially tip the balance of Aβ metabolism away from amyloid.
- Lesley Jones on Dreaded Anticipation: ALS Strikes Earlier in Successive Generations
- Simon Vann Jones on Do 'Headers' Rack Up Brain Damage in Soccer Players?
- Ann McKee on Do 'Headers' Rack Up Brain Damage in Soccer Players?
- Jochen Herms on Ocular indicators of Alzheimer's: exploring disease in the retina.
- Thomas Beach on Ocular indicators of Alzheimer's: exploring disease in the retina.
- Jochen Herms on Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
- Paul Aisen on Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
- Bart De Strooper on Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
- Stefan Lichtenthaler on Merck Pulls Plug on Phase 2/3 BACE Inhibitor Trial
- William Goure on CTAD: Solanezumab Seen to Nudge AD Ever so Slightly
- Ian Clark on After Solanezumab: Where Should Alzheimer’s Research Go?
- Oskar Hansson on Touchdown for NfL: Blood Test Tells Parkinson's from Related Disorders
- Andy Shih on Pericytes Don’t Go With the Flow—They Change It
- Lei Feng on Being Bilingual Buffers Against Alzheimer’s by Improving Connectivity
- Pedro Rosa-Neto on Do Astrocytes Blur the PET Signal for ‘Neuronal’ Activity?
- Anusha Mishra on Pericytes Don’t Go With the Flow—They Change It
- Michael Lardelli on Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase.
- Marcel Verbeek on Touchdown for NfL: Blood Test Tells Parkinson's from Related Disorders
- Scott Small and Gregory A. Petsko on Lindquist Leaves Behind Parkinson’s Interactome as Her Parting Gift
- Kassandra Kisler, Amy Nelson and Berislav Zlokovic on Pericytes Don’t Go With the Flow—They Change It
- Michele Vendruscolo on Building ProteomeTools based on a complete synthetic human proteome.